無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗真菌剤市場分析:薬剤クラス別 (アゾール、エキノカンジン、ポリエン、アリルアミン)、適応別 (皮膚糸状菌症、アスペルギルス症、カンジダ症) のセグメント予測

Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 408955
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
抗真菌剤市場分析:薬剤クラス別 (アゾール、エキノカンジン、ポリエン、アリルアミン)、適応別 (皮膚糸状菌症、アスペルギルス症、カンジダ症) のセグメント予測 Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025
出版日: 2016年11月24日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界の抗真菌剤市場について調査し、市場の動向、薬剤クラス別、適応別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 調査方法

第2章 エグゼクティブサマリー

第3章 市場の変動、動向、範囲

  • 市場セグメンテーション
    • 促進因子分析
    • 阻害因子分析
  • 浸透・成長見通しマッピング
  • PESTLE分析
  • 業界分析:ポーターズ

第4章 薬剤クラス別予測・動向分析

  • 薬剤クラス別動向分析
  • アゾール
  • エキノカンジン
  • ポリエン
  • アリルアミン
  • その他

第5章 適応別予測・動向分析

  • 適応別動向分析
  • 皮膚糸状菌症
  • アスペルギルス症
  • カンジダ症
  • その他

第6章 地域別予測・動向分析

  • 地域別市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合環境

  • 戦略枠組み
  • 市場参入分類
  • 企業プロファイル
目次
Product Code: GVR-1-68038-293-8

The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key contributing factor for the growth of the antifungal drugs market in the coming years. Rising adoption of immunosuppressive andantineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics have resulted in the increasing incidence of fungal infections in the recent years.

The growing geriatric population prone to infectious diseases and higher prevalence of chronic conditions, including HIV and cancer, are further contributing toward the rising demand for antifungals to treat opportunistic fungal infections over the forecast period. The large demand for these fungistatic agents is due to the nature of fungal infections, which are difficult to diagnose, yielding high mortality and morbidity rates.

Further Key Findings from the Study Suggest:

  • Echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks
  • Candidiasis indication segment is anticipated to witness the fastest CAGR over the forecast period due to the increasing drug resistance of the Candida speciesto Azoles
  • North America held the largest market share as of 2015, which is attributable to higher awareness levels pertaining to the treatment of fungal infection and presence of target diseases in the population
  • Asia pacific is predicted to exhibit the fastest growth due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases amongst the population
  • The companies are focusing on the development of effective therapeutic agents for the treatment of systemic fungal infections in immune-compromised patients
  • Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics is predicted to provide this market with lucrative growth opportunities
  • For example, the public-private partnership, namely Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator is anticipated to provide USD 44 million in 2016 and around USD 350 million in the coming 5 years to boost the R&D pipeline
  • The partners involved in this partnership are the U.S. Department of Health and Human Services, the Antimicrobial Resistance Centrein England, and Boston University School of Law

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Region Wise Market Calculation
    • 1.1.1 Region Wise Market: Base Estimates
    • 1.1.2 Global Market: CAGR Calculation
  • 1.2 Region based segment share calculation
  • 1.3 List of Secondary Sources

Chapter 2 Executive Summary

Chapter 3 Market VariabAllyamines, Trends& Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing incidences of fungal infections
      • 3.1.1.2 Increasing R&D pertaining to the development of novel drugs
      • 3.1.1.3 Increasing awareness levels
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Resistance to antifungal drugs
      • 3.1.2.2 Presence of generic competition
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Antifungal Drugs - PESTLE Analysis
  • 3.4 Industry Analysis - Porter's

Chapter 4 Market Categorization 1: Drug Class Estimates & Trend Analysis

  • 4.1 Antifungal Drugs Market: Drug Class Movement Analysis
  • 4.2 AzoAllyamines
    • 4.2.1 AzoAllyamines market, 2014 - 2025 (USD Million)
  • 4.3 Echinocandins
    • 4.3.1 Echinocandins market, 2014 - 2025 (USD Million)
  • 4.4 Polyenes
    • 4.4.1 Polyenes market, 2014 - 2025 (USD Million)
  • 4.5 Allylamines
    • 4.5.1 Allylamines market, 2014 - 2025 (USD Million)
  • 4.6 Others
    • 4.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 Market Categorization : Indication Estimates & Trend Analysis

  • 5.1 Antifungal Drugs Market: indication Movement Analysis
  • 5.2 Dermatophytosis
    • 5.2.1 Dermatophytosis market, 2014 - 2025 (USD Million)
  • 5.3 Aspergillosis
    • 5.3.1 Aspergillosis market, 2014 - 2025 (USD Million)
  • 5.4 Candidiasis
    • 5.4.1 Candidiasis market, 2014 - 2025 (USD Million)
  • 5.5 Others
    • 5.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Market Categorization : Regional Estimates & Trend Analysis, by Drug Class and Indications

  • 6.1 Antifungal Drugs market share by region, 2015 & 2024
  • 6.2 North America
    • 6.2.1 North America antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.3.2 UK
      • 6.3.2.1 UK antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Japan antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 India antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA antifungal drugs market, 2014 - 2025 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa antifungal drugs market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Market participation categorization
  • 7.3 Company Profiles
    • 7.3.1 Novartis
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 Pfizer Inc.
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 Bayer Healthcare
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 ProductBenchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 Sanofi-Aventis
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 Merck & Co. Inc.
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 GlaxoSmithKline
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product Benchmarking
    • 7.3.7 Abbott Laboratories
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 Glenmark Pharmaceuticals Ltd
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 Enzon Pharmaceuticals
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 ID Sigma-Aldrich Corporation
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 Astellas Pharma Inc
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product Benchmarking
      • 7.3.11.4 Strategic Initiatives

List of Tables

  • TABLE 1 North America antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 2 North America antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 3 U.S. antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 4 U.S. antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 5 Canada antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 6 Canada antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 7 Europe antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 8 Europe antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 9 UK antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 10 UK antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 11 Germany antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 12 Germany antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 13 Asia Pacific antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 14 Asia Pacific antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 15 Japan antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 16 Japan antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 17 China antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 18 China antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 19 India antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 20 India antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 21 Latin America antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 22 Latin America antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 23 Brazil antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 24 Brazil antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 25 Mexico antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 26 Mexico antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 27 MEA antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 28 MEA antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
  • TABLE 29 South Africa antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
  • TABLE 30 South Africa antifungal drugs market, by Indications, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 U.S. FDA ADR reports, 2006-2015
  • FIG. 6 Market restraint relevance analysis (Current & future impact)
  • FIG. 7 Penetration & Growth Prospect Mapping
  • FIG. 8 Antifungal Drugs PESTLE Analysis
  • FIG. 9 Porter's Five Forces Analysis
  • FIG. 10 Antifungal Drugs market drug class outlook key takeaways
  • FIG. 11 Antifungal Drugs market: Drug class movement analysis
  • FIG. 12 AzoAllyamines market, 2014 - 2025 (USD Million)
  • FIG. 13 Echinocandins market, 2014 - 2025 (USD Million)
  • FIG. 14 Polyenes market, 2014 - 2025 (USD Million)
  • FIG. 15 Allylamines market, 2014 - 2025 (USD Million)
  • FIG. 16 Others market, 2014 - 2025 (USD Million)
  • FIG. 17 Antifungal Drugs market indication outlook key takeaways
  • FIG. 18 Antifungal Drugs market: Indications movement analysis
  • FIG. 19 Dermatophytosis market, 2014 - 2025 (USD Million)
  • FIG. 20 Aspergillosis market, 2014 - 2025 (USD Million)
  • FIG. 21 Candidiasis market, 2014 - 2025 (USD Million)
  • FIG. 22 Others market, 2014 - 2025 (USD Million)
  • FIG. 23 Regional marketplace: Key takeaways
  • FIG. 24 Regional outlook, 2015 & 2024
  • FIG. 25 North America antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 26 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 27 Canada antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 28 Europe antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 29 UK antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 30 Germany antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 31 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 32 Japan antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 33 China antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 34 India antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 35 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 36 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 37 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 38 MEA antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 39 South Africa antifungal drugs market, 2014 - 2025 (USD Million)
  • FIG. 40 Strategy framework
  • FIG. 41 Participant categorization
Back to Top